威世药业

Vesy Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets metabolic diseases, oncology, and autoimmune disorders. Its lead candidate, VS-101 (Vesnurat), is a potent URAT1 inhibitor currently in clinical development for the treatment of hyperuricemia and gout. Vesy leverages its internal R&D platform to advance a pipeline of high-potential candidates aimed at addressing significant unmet medical needs in global markets. The company is backed by prominent venture capital firms and maintains a strong focus on translational medicine and efficient clinical execution.